



JFW 44

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PAULS, et al.

Application No.: **10/616,141**

Examiner: **JOHNSEN, Jason H.**

Art Unit: **1623**

Filed: **07/08/2003**

Title: **1-AROYL-PIPERIDINYL BENZAMIDINES**

Certificate of Mailing or Transmission	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop Amendment address below, or being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	<u>February 3, 2006</u>
Printed Name of Person Signing Certificate <u>Renée McMinnis</u>	
Signature	<u>Renée McMinnis</u>

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.


Respectfully submitted,

February 3, 2006

Julie Anne Knight
Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3744
Telefax (908) 231-2626

sanofi-aventis Docket No. USA3676 US CNT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Info Application of
PAULS, et al.

Examiner: JOHNSEN, Jason H.

Art Unit: 1623

Application No.: **10/616,141**

Filed: **07/08/2003**

Title: **1-AROYL-PIPERIDINYL BENZAMIDINES**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 3, 2006

Date of Deposit

Renee M. Minnis

Signature

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

02/07/2006 EFLORES 00000017 181982 10616141

01 FC:1806 180.00 DA

(b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

(1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

(2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or


(3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The reference "Rote Liste" is a handbook that lists all medicaments, which are approved in Germany. It is issued at the beginning of each year. The "chapter 01 of "Rote Liste" is directed to all appetite suppressants and slimming agents, which are approved in Germany.

Respectfully submitted,

February 3, 2006




Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626
sanofi-aventis Docket No. DEAV2001/0047 US NP

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

<p>Substitute for form 1449A/PTO</p> <p>6 INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete in ink....	
Sheet	1	of	4	Application Number	10/616,141
				Filing Date	07/08/2003
				First Named Inventor	PAULS, et al.
				Group Art Unit	1623
				Examiner Name	JOHNSON, Jason H.
				Attorney Docket Number	USA3676 - US - CNT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/616,141
(use as many sheets as necessary)				Filing Date	07/08/2003
Sheet	2	of	4	First Named Inventor	PAULS, et al.
				Group Art Unit	1623
				Examiner Name	JOHNSEN, Jason H.
				Attorney Docket Number	USA3676 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		BEIL, W., et al., Phenotypic and Functional Characterization of Mast Cells Derived from Renal Tumor Tissues, Experimental Hematology Vol. 26, 1998, pages 158-169
		BISCHOFF, S C., et al., Quantitative Assessment of Intestinal Eosinophils and Mast Cells in Inflammatory Bowel Disease, Histopathology 1996, Vol. 28, pages 1-13
		BROERSMA, et al., The Effect Of Thrombin Inhibition In a Rat Arterial Thrombosis Model, Thrombosis Research 64; 405-412, 1991
		BUCKLEY, M., et al., Mast Cell Subpopulations in the Synovial Tissue of Patients with Osteoarthritis: Selective Increase in Numbers of Tryptase-positive, Chymase-negative Mast Cells, Journal of Pathology, Vol. 186, 1998, pages 67-74
		CAIRNS, et al., Mast Cell Tryptase Stimulates the Synthesis of Type I Collagenin Human Lung Fibroblasts, J. Clin. Invest., Vol. 99, Number 6, March 1997, pages 1313-1321
		CAUGHEY, G., et al., Substance P and Vasoactive Intestinal Peptide Degradation by Mast Cell Tryptase and Chymase, The Journal of Pharmacology and Experimental Therapeutics, (1988) , Vol. 244, No. 1, pages 133-137
		FRANCONI, G., et al. et al., Mast Cell Tryptase and Chymase Reverse Airway Smooth Muscle Relaxation Induced by Vasoactive Intestinal Peptide in the Ferret, The Journal of Pharmacology and Experimental Therapeutics, (1989), Vol. 248, No. 3, pages 947-951
		HASEBE, et al., Photochemical generation of aliphatic radicals from benzophenone oxime esters: simple synthesis of alkylbenzenes and alkylpyridines, CAS Abstr. 106:119639-1987:119639, Hasebe et al, Tetr. Lett 27/28,3239-42(1986)
		HIGUCHI, T., et al., Pro-drugs as Novel Drug Delivery Systems, ACS Symposium Series, Vol. 14
		HOLST, et al., Antithrombotic Effect of Recombinant Truncated Tissue Factor Pathway Inhibitor (TFPI 1-161) in Experimental Venous Thrombosis- A Comparison with Low Molecular Weight Heparin, Thrombosis and Haemostasis, 71 (2) 214-219 (1994)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	4	Application Number	10/616,141
				Filing Date	07/08/2003
				First Named Inventor	PAULS, et al.
				Group Art Unit	1623
				Examiner Name	JOHNSEN, Jason H.
				Attorney Docket Number	USA3676 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		IRANI, et al., Human Conjunctival Mast Cells: Distribution of MCT and MCTC in Vernal Conjunctivitis and Giant Papillary Conjunctivitis, Journal of Allergy and Clinical Immunology, Volume 86, Number 1 pages 34-40	
		JARVIKALLIO, A, et al., Quantitative Analysis of Tryptase- and Chymase-containing Mast Cells in Atopic Dermatitis and Nummular Eczema, British Journal of Dermatology 1997, Vol. 136, pages 871-877	
		JEZIORSKA, M, et al., Mast Cell Distribution, Activation, and Phenotype in Atherosclerotic Lesions of Human Carotid Arteries, Journal of Pathology, Vol. 182, 1997, pages 115-122	
		KOMOTO, et a., Preparation of .alpha.-[(N-benzoylpiperidinyl) phenoxy] isobutyrate and analogs as hypolipemics, CAS Abstr. 122:81127-1995:58673, Komoto et al, CA 2110095/6/1994	
		KURZ, et al., Rat Model Of Arterial Thrombosis Induced By Ferric Chloride, Thrombosis Research 60; 269-280, 1990	
		MCEUEN, et al., Guinea Pig Lung Tryptase, Biochemical Pharmacology, Vol. 52, pp. 331-340, 1996	
		NAUKKARINEN, A, et al., Immunohistochemical Analysis of Sensory Nerves and Neuropeptides, and Their Contacts with Mast Cells in Developing and Mature Psoriatic Lesions, Archives of Dermatological Research Vol. 285, 1993 pages 341-346	
		ROCHE, E., et al., Bioreversible Carriers in Drug Design Theory and Application, American Pharmaceutical Association and Pergamon Press, 1987	
		RUOSS, Stephen J, et al., Mast Cell Tryptase is a Mitogen for Cultured Fibroblasts, J. Clin. Invest., Vol. 88, August 1991, pages 493-499	
		SCHWARTZ, L., et al., The a Form of Human Tryptase Is the Predominant Type Present in Blood at Baseline in Normal Subjects and Is Elevated in Those with Systemic Mastocytosis, The Journal of Clinical Investigation, Vol. 96, December 1995, pages 2702-2710	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/616,141
Sheet	4	of	4	Filing Date	07/08/2003
				First Named Inventor	PAULS, et al.
				Group Art Unit	1623
				Examiner Name	JOHNSEN, Jason H.
				Attorney Docket Number	USA3676 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		SEKIZAWA, K., et al., Mast Cell Tryptase Causes Airway Smooth Muscle Hyperresponsiveness in Dogs, J. Clin. Invest., Vol. 83, January 1989, pages 175-179
		STEINHOFF, M., et al., Agonists of Proteinase-activated Receptor 2 Induce Inflammation by a Neurogenic Mechanism, Nature Medicine, Vol. 6, Number 2, February 2000, pages 151-158
		TAM, et al., Degradation of Airway Neuropeptides by Human Lung Tryptase, Am. J. Respir. Cell Mol. Biol. Vol. 3, 1990, pages 27-32
		TETLOW, L., et al., Distribution, Activation and Tryptase/Chymase Phenotype of Mast Cells in the Rheumatoid Lesion, Annals of the Rheumatic Diseases 1995; Vol. 54, pages 549-555
		WILSON, S J., et al., Inflammatory Mediators in Naturally Occurring Rhinitis, Clinical and Experimental Allergy, 1998, Vol. 28, pages 220-227
		ZHANG, M., et al., Mast Cell Tryptase and Asthma, Mediators of Inflammation, Vol. 6, 1997, pages 311-317

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.